Medy-Tox Inc. (KOSDAQ:086900)
South Korea flag South Korea · Delayed Price · Currency is KRW
141,800
+3,800 (2.75%)
Apr 1, 2025, 3:30 PM KST

Medy-Tox Revenue

In the year 2024, Medy-Tox had annual revenue of 228.62B KRW with 3.39% growth. Medy-Tox had revenue of 55.18B in the quarter ending December 31, 2024, a decrease of -18.86%.

Revenue
228.62B
Revenue Growth
+3.39%
P/S Ratio
4.42
Revenue / Employee
317.09M
Employees
721
Market Cap
944.31B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2024228.62B7.50B3.39%
Dec 31, 2023221.12B26.02B13.34%
Dec 31, 2022195.10B10.23B5.53%
Dec 31, 2021184.87B44.04B31.27%
Dec 31, 2020140.83B-65.07B-31.60%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Samsung Biologics 4,547.32B
Celltrion 3,557.30B
ALTEOGEN 102.85B
Yuhan 2,067.79B
SK Biopharmaceuticals 547.60B
HLB Co., Ltd. 51.92B
Sam Chun Dang Pharm. 210.92B
PharmaResearch 350.12B
Revenue Rankings